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Background. We encountered repeatedly, in our clinical practice, discordant results between UBT and histopathology about H.
pylori infection. Goal. To study the diagnostic accuracy of Heliprobe 14C-urea breath test (14C-UBT) for detection of H. pylori
infection in an Iranian population. Study. We enrolled 125 dyspeptic patients in our study. All of them underwent gastroscopy,
and four gastric biopsies (three from the antrum and one from the corpus) were obtained. One of the antral biopsies was utilized
for a rapid urease test (RUT), and three others were evaluated under microscopic examination. Sera from all patients were
investigated for the presence of H. pylori IgG antibodies. The 14C-UBT was performed on all subjects using Heliprobe kit, and
results were analyzed against the following gold standard (GS): H. pylori infection considered positive when any two of three
diagnostic methods (histopathology, RUT, serology) are positive. Results. According to data analysis, the Heliprobe 14C-UBT had
94% sensitivity, 100% speciﬁcity, 93% negative predictive value (NPV), 100% positive predictive value (PPV), and 97% accuracy,
compared with GS. Conclusion. The Heliprobe 14C-UBT is an easy-to-perform, rapid-response, and accurate test for H. pylori
diagnosis,suitable for oﬃce use.
1.Introduction
Helicobacter pylori (H. pylori) is a spiral shaped microae-
rophilic gram-negative bacterium that resides in the gastric
epithelial mucosa and induces an inﬂammatory response
leading to gastritis and peptic ulcer disease [1, 2]. It has been
implicated as playing a role in gastrointestinal malignancies,
especially gastric adenocarcinoma and MALToma until the
latter could be treated with H. pylori eradication [3, 4].
H. pylori h a saw o r l d w i d ep r e v a l e n c er a t eo fa b o u t5 0 % ,
with a higher prevalence in developing countries [5, 6].
According to population-based studies, it has been shown
that the H. pylori infection rate is very high in the Iranian
population [7].
H. pylori detection can be made with diverse diagnostic
tests, which are technically divided into invasive and non-
invasive based on whether endoscopy is required or not.
Invasive tests oﬀerthe possibility ofobtaining tissue samples,
which can be used for a rapid urease test (RUT), culture,
polymerase chain reaction (PCR), and histopathologic eval-
uation. Noninvasive tests include serum H. pylori IgG
antibody titer, the urea breathtest (UBT), and H. pylori stool
antigen assay. Compared to noninvasive diagnostic modes,
however, invasive techniques are inconvenient for patients
and also have higher cost [8].
A UBT diagnostic test is based on the fact that swallowed
“labeled carbon-containing urea” is broken down to ammo-
nia and carbon dioxide (CO2) by the urease-producing
microorganism (H.pylori) inthegastric mucosa,and,ﬁnally,
taggedcarbonwithin theliberatedCO2 isdetectedinexhaled
breath samples [9, 10].
Between two carbon isotopes (13Ca n d14C), which are
used for the UBT, the 13C isotope has the diﬃculty of requir-
ing more complex equipment, such as a mass spectropho-
tometer and administration of a pretest meal such as citric
acid. However, when the 14C isotope is utilized, the required
equipment is only a portable compact beta-scintillation
counter, which oﬀers the convenience of performing the test2 Gastroenterology Research and Practice
in the oﬃce. Although the 14C isotope is radioactive, micro-
dose (1µCi) 14C has the minimal radiation of one day back-
ground exposure [11].
We encountered repeatedly, dyspeptic patients, in our
clinical practice, whose UBT results were not consistent with
histopathology about H. pylori infection; based on Heli-
cobacter genetic polymorphisms and diﬀerences between H.
pylori strains in diﬀerent countries, and since clinical valida-
tion of Heliprobe 14C-UBT has not yet been investigated in




We studied 125 consecutive patients with dyspepsia that had
beenreferred for upperGI endoscopy. We deﬁned dyspepsia,
based on the Rome III criteria, as having one or more
of the following conditions: postprandial fullness (termed
postprandial distress syndrome), early satiation (inability
to ﬁnish a normal-sized meal or postprandial fullness),
and epigastric pain or burning (termed epigastric pain
syndrome) [15].
We considered subjects aged 15y–75y. We excluded
patients who had been using proton pump inhibitors, H2
blockers,or any antibiotics within fourpreviousweeks of the
endoscopic evaluation. Pregnant women, patients who had
ah i s t o r yo fH. pylori eradication, and those with any severe
cardiopulmonarydisordersordebilitatingorlife-threatening
conditions were excluded as well. Study personnel were
blinded as to patient test results. The study protocol was
approved by the ethics committee of the Gastrointestinal
and Liver Diseases Research Center of Guilan University
of Medical Sciences, and written informed consents were
obtained from each participant.
After an overnight fast, patients underwent gastroscopy
with a FUJINON endoscope, and four separate gastric
biopsieswere taken,three from theantrum and one from the
corpus.One ofthe antral samples was used fora rapid urease
test (RUT), and two antral samples plus the corpus biopsy
sample were used for histopathologic examination.
To perform the RUT, we utilized a home-made liquid
rapid urease kit (Gastric Urease, Bahar Afshan Co., Iran).
We put tissue samples in a yellow-colored reagent liquid,
and results were read after 30min, 60min, and ﬁnally after
24 hours. Liquid color changes into deep red, purple, or vio-
let indicated a positive result. Negative results were indicated
by no color change. Tissue samples were prepared with stan-
dard hematoxylin and eosin (H&E) and Giemsa stainings
for histopathologic investigation. The histopathology exam
result was considered positive when H. pylori was detected in
either of the stains and negative when the organism was not
detected in any.
One blood sample was obtained from each patient
to be examined for anti H. pylori IgG titer. We utilized
the ELIZA method (LDN, Nordhorn, Germany), and sera
with titers that were >11 international units (IU) were
consideredpositive(testcut-oﬀpoint:10IU,<9IU:negative,
9–11IU: doubtful, >1 1I U :p o s i t i v e ) ;w er e g a r d e dd o u b t f u l
results as negative.
After gastroscopy, we performed Heliprobe 14C-UBT
tests. In order to carry out the UBT, after an overnight
fast, the patient swallowed a 14C-labeled urea-containing
capsule (Helicap, Institute of Isotopes, Budapest, Hungary)
with water. The overall activity of these capsules is as small
as 1µCi (37KBq). After 15 minutes, the patient breathed
out into a dry cartridge (Heliprobe breath card, Kibion
AB, Uppsala, Sweden) through its mouthpiece until the
color of the card indicator changed from orange to yellow,
which took about 1min to 2min. Thereafter, the breath card
was inserted into a small desktop Geiger M¨ uller counter
(Heliprobe Analyser, Kibion AB, Uppsala, Sweden), and
the radioactivity of the breath samples was read after 250
seconds ofanautomated process. Finally,thetest resultswere
expressed on the LCD of the analyzer in a numeric fashion
(0: patient not infected, 1: borderline result, 2: patient in-
fected), which corresponded to radioactivity as count per
minute (CPM): <25CPM: patient not infected, 25–50CPM:
borderline result, >50CPM: patient infected. We considered
grades 0 and 1 as negative results in our study, and
only samples with activities that were more than 50CPM
(expressed as no. 2 on the counter LCD) were regarded as
positive.
Descriptive analysis was done for demographic features.
Goldstandard forH.pylori positivity wasdeﬁnedas“positive
results for any two of three diagnostic methods (histopathol-
ogy, RUT, serology).” Sensitivity, speciﬁcity, negative and
positive predictive values (NPV and PPV), and the accuracy
of the UBT were computed against our GS; for categorical
variables, 95% conﬁdence interval (95% CI) was calculated.
3.Results
We enrolled 125 consecutive patients in our study according
to the above mentioned inclusion and exclusion criteria; 65
(52%) were females, and 60 (48%) were males. Patient ages
ranged from 18y to 66y with a mean of 35.81 ± 12.97y.
As a result of histopathologic evaluation of tissue spec-
imens, 69 (55.2%) patients were found to be infected with
H. pylori, and 56 (44.8%) were not infected. Serologic
examination of patient sera samples for IgG antibody against
H. pylori showed 87 (69.6%) positive results, while the
remaining 38 (30.4%) were seronegative. The RUT results
were positive in 63 (50.4%) patients and negative in 62
(49.2%)patients.H.pyloriinfection wasfoundin67(53.6%)
subjects by the 14C urea breath test (14C-UBT), and 58
(46.4%) subjects were negative.
All four tests were positive or negative in 57 (45.6%)
and 34 (27.2%) patients, respectively. Only 2 patients had
no histopathologic evidence of H. pylori infection, whilst
their RUT and serology results were positive. (Incidentally
these two patients also had positive UBTs.); We think that
this might be the result of errors during sampling or
histopathologic examination. 20 patients showed solitary
positive serology tests which indicated recent past infection.
Table 1 shows other discordances between our test results.Gastroenterology Research and Practice 3
Table 1: Distribution ofH. pylori diagnostictest discordant results.
Patients (n) Histology RUT Serology UBT
5 7 + +++
4+ + − +
4+ − ++
4+ − + −
2 − +++
20 −−+ −
34 −− − −
RUT: rapid urease test; UBT: urea breath test; +: positive; −: negative; n:
number.
Compared to our GS, the UBT could correctly detect
67 of 71 H. pylori infected subjects with 94% sensitivity
(95% CI: 85–98%) and 100% positive predictive value (PPV;
95% CI: 93–100%). The UBT also excluded correctly all
54 uninfected patients with 100% speciﬁcity (95% CI: 92–
100%)and negative predictivevalue (NPV) of93% (95% CI:
82–98%). The UBT showed 97% accuracy (Table 2).
4.Discussion
H. pylori has a high prevalence rate in developing countries,
suchasIran.AccordingtodatareportedbyDerakhshanetal.,
H. pylori must be considered a risk factor for noncardiac
gastric adenocarcinoma in Iranian patient [16]. Eradication
of H. pylori could lower the incidence rate of gastric cancer
[17]. A more precise diagnosis of H. pylori, allowing an
earlier eradicating treatment, may play a crucial role in
cancerpreventionstrategies. Currently, there is an increasing
need for an easy-to-perform, accurate, and readily available
diagnostic technique in H. pylori prevalent populations.
Considering economic concerns and the availability of tests
in developing countries, as well as testing possibilities in
medical clinics, we recommend use of the Heliprobe 14C-
UBT over other noninvasive and invasive tests.
Based on the data that suggest that the combination of
tests increases their overall diagnostic power, we combined
H.pylori serologicassessment and theRUTwithhistopathol-
ogy in order to account for the possibility of very few false
negative results from microscopic examination (which were
seen in two cases in our study) [18]. We discovered that the
14C-UBT has 94% sensitivity, 100% speciﬁcity, 100% PPV,
93% NPV, and 97% accuracy, compared with GS. These
ﬁndings are compatible with Jonaitis et al.’s study results,
with their deﬁned H. pylori positive gold standard as “at least
one positive test of RUT or histopathology”. They found that
Heliprobe had 92% sensitivity, 100% speciﬁcity, 100% PPV,
84% NPV, and 94% accuracy [19]. Our results are also in
accordancewith Ozdemiret al.’sresultsforHeliprobeperfor-
mance(96.6%sensitivity,100%speciﬁcity,93.7%PPV,100%
NPV, and 97.7% accuracy), although their H. pylori positive
gold standard was deﬁned as “positivity of any two of the
three following tests (RUT, PCR, and histopathology)” [20].
In Rasool et al.’s study regarding histopathology alone
as GS, Heliprobe sensitivity, speciﬁcity, NPV, PPV, and
accuracy were 92%, 93%, 84%, 97%, and 93%, respectively,
which were consistent with our results although the studies’
gold standards are slightly diﬀerent [21]. In another study,
conducted by ¨ Ozt¨ urk et al. that is again regarding only
histopathology as GS, Heliprobe had higher sensitivity
(100%), but its speciﬁcity (76%) was lower than that of our
study [22].
People who undergo medical diagnostic tests using ra-
dioisotopes are often worried about radiation exposure.
T h eh a l fl i f eo ft h e14C isotope is about 5000 years, but,
with regards to the short biologic half life of urea, more
than two-thirds of the tagged urea will be excreted in the
urine within the following three days of the test; moreover,
the total dose of the 14C used in the test is very low,
and activity of this quantity of isotope was evaluated as
1µCi. Accordingly, based on the published data, about 800
breath testing episodes must be carried out for one person
to receive an eﬀective dose equivalent to the amount that
an average person absorbs from natural sources in one
year [23]. Considering the few times a person needs to be
tested with the 14C-UBT, the lifelong cumulative radiation
of the test is negligible. Even in conditions of repeated UBT
testing, radiation exposure risk is very low. Previously, 14C-
UBT was not used in children because of the concerns
about the radiation hazards; however, diverse studies have
established its safety in pediatric patients [11, 24]. Although
no experimental study has yet been done to assess 14C-UBT
safety in pregnancy, Bentur et al. have claimed that, in view
of the insigniﬁcant 14C radioactivity, fetal radiation exposure
is extremely lower than teratogenic thresholds [25].
One of the advantages of the Heliprobe system is that it
can be used in a clinical setting, allowing the preparation of
test results on-site in less than one hour. The portable beta-
scintillation counter that is used in this test could simply
be placed on a desktop; however, the 13C-UBT needs a
sophisticated mass spectrophotometer to read the results. Of
course, 13C-UBT has some advantages over 14C-UBT such
that the former utilizes a nonradioactive isotope that makes
it suitable to use in pregnant women and children. Although
some studies, as mentioned earlier, have already emphasized
on 14C-UBT safety in children, 13C-UBT is still the preferred
method in them. Considering 13C safety, it is also a better
isotope than 14C for epidemiologic studies, as some studies
used it to investigate H. pylori routes of transmission in
preschool age [26, 27].
Stool antigen is another sensitive and speciﬁc nonin-
vasive diagnostic test for H. pylori [28]. Although it is
competitive with the 14C-UBT in terms of accuracy, but
it is not appropriate for oﬃce use because it is a time
consuming exam regarding sampling limitations and oﬀ-site
test interpretation.
Conclusively, compared to invasive gold standards, the
Heliprobe 14C-UBT is an accurate, sensitive, and speciﬁc
test for H. pylori diagnosis. The main advantages of the
Heliprobe 14C-UBT are its rapidity and patient convenience.
Furthermore, in view of the very low radioactivity of the
Heliprobe 14C-UBT and its portability, this test seems to be
am o r es u i t a b l eo p t i o nf o ro ﬃce use than a nonradioactive,
complex and oﬀ-site 13C - U B Ta sw e l la so t h e ri n v a s i v e
diagnostic modalities.4 Gastroenterology Research and Practice
Table 2: Diagnostic performance of Heliprobe 14C-UBT against gold standard.
Heliprope 14C-UBT compared to: Sensitivity (95% CI) Speciﬁcity (95% CI) PPV (95% CI) NPV (95% CI) Accuracy (95% CI)
Gold standard 94% (85–98%) 100% (92–100%) 100% (93–100%) 93% (82–98%) 97%
14C-UBT: urea breath test with labeled carbon-14; RUT: rapid urease test; PPV: positive predictive value; NPV: negative predictive value; CI: conﬁdence
interval. For gold standard deﬁnitions refer to the text.
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